Optimizing Antiplatelet Therapy in Cardiogenic Shock-The Pharmacodynamics of Antiplatelet and Antithrombotic Therapies in Cardiogenic Shock: How to Mitigate Ischemia and Bleeding

The Pharmacodynamics of Antiplatelet and Antithrombotic Therapies in Cardiogenic Shock: How to Mitigate Ischemia and Bleeding

Back to course

Video Transcription

Video Summary

In this video, the speaker discusses the importance of anti-platelet and anti-thrombin treatment in revascularization procedures for cardiogenic shock. They emphasize the need for good results in order to prevent complications such as ischemic events and stent thrombosis. The speaker also mentions the challenges in providing adequate anti-platelet therapy in certain patient populations, such as those with cardiogenic shock and out-of-hospital cardiac arrest. They suggest that intravenous anti-platelet options like cangrelor may be a better choice in these cases. Overall, the video highlights the significance of proper anti-platelet treatment in improving outcomes in revascularization procedures.

Asset Subtitle

Timothy D. Henry, MD, MSCAI

Keywords

anti-platelet treatment

anti-thrombin treatment

revascularization procedures

cardiogenic shock

ischemic events